Roth Capital Assigns Buy On Shares Of Verastem, $29 PT
Roth Capital analyst Joseph Pantginis assigned a Buy rating on Verastem (NASDAQ:VSTM) with a $29 price target, which represents a potential upside of 188% from where the stock is currently trading.
Pantginis wrote, “VSTM announced 3Q14 results, posting EPS of ($0.52), in line with our estimate and the consensus estimate. The company’s clinical programs are moving full steam ahead into 2015. An interim analysis fraom the pivotal COMMAND study of VS-6063 in mesothelioma is expected mid-2015. We believe positive results from the recent Window of Opportunity study of ‘6063 demonstrate the drug’s potential efficacy in this indication and bode well for COMMAND.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -7.1% and a 43.0% success rate. Pantginis has a -33.8% average return when recommending VSTM, and is ranked #3312 out of 3354 analysts.